Services
Health Economics and Outcomes Research (HEOR)
Using our comprehensive real-world data access to develop real-world evidence that supports data-driven decision making and market differentiation.Overview
Beyond the Limits of
Clinical Trials
Clinical trials remain the gold standard for assessing the safety and efficacy of a medical product. Yet, as more drugs obtain accelerated approval, FDA seeks to complement clinical trial results with real-world data that provide a fuller picture of product safety and effectiveness. Health Economics and Outcomes Research (HEOR) can play a crucial role in assembling that picture, as well as in highlighting advantages of specific therapies that manufacturers can use to differentiate their products from alternatives (e.g., preferred by patients, fewer side effects, lower total cost of care, and improved quality of life).
Data sources for HEOR are readily available, but the data themselves offer only a partial picture. Clients seeking accurate, real-world assessments of patient outcomes and costs must partner with someone who can access a wider range of data assets, assess them, and advise accordingly to address strategic business priorities.
Providing Clients with Actionable Insights
Our team includes well published researchers, pharmacists, and physicians as well as statisticians, health economists, and other public health experts who have worked for payers, providers, government agencies, and pharmaceutical companies. We apply this broad perspective to a wide range of datasets, thus providing clients with the real-world information and analysis needed to optimize early clinical development.
Our Approach
A Complete Picture of the Patient Journey
We have access to Inovalon’s robust data that includes more than 63 billion medical events and hundreds of millions of unique patients across commercial fee-for-service Medicare (100%), Medicare Part D (100%), Medicare Advantage, and managed Medicaid populations. This wealth of information offers a longitudinal view of patients’ use of healthcare and resulting health outcomes.
Our combination of data access and analytical capabilities enables us to connect those data across the healthcare ecosystem, even if a patient’s journey spans multiple states, plans, and therapies. By using deterministic matching to link disparate events, we can reconstruct a patient’s full journey, including time from diagnosis to treatment, duration of treatment, post-diagnosis survival, additional treatments, lab results, and more. We can also provide total cost-of-care analysis, including inpatient hospital stays or other medication needed to manage side effects, and assess revenue opportunities and value-based benefits.
How Can We Help?
Engage An Avalere Expert Today.
Engage An Avalere Expert Today.
Featured Experts
Featured Health Economics and Outcomes Research (HEOR) Experts
Taylor Schwartz
Managing Director
Taylor Schwartz works collaboratively with clients to develop, design, and execute epidemiological and health economics and outcomes research studies in a variety of therapeutic areas, in addition to health policy analyses and medical innovation value assessment studies.
Laura Housman
Practice Director
Laura T. Housman, MPH, MBA, DrPH candidate (ABD) is Practice Director of the Evidence and Strategy practice within Avalere Health, bringing broad and extensive expertise in strategy, evidence generation, reimbursement and pricing, patient communications, population health and personalized medicine to drive access to innovation across healthcare.
Josie Lloyd
Consultant II
Josie Lloyd supports clients in developing and executing research projects across a range of therapeutic areas, with a focus on value strategy and health economics and outcomes research.
Related Services
